Development of effective messages to promote maternal immunization in Kenya

Frew, Paula M.; González-Casanova, Inés; Otieno, Nancy A.; Malik, Farnaz; Fenimore, Vincent L.; Owino, Dominique; Adero, Maxwell O.; Atito, Raphael; Bigogod, Godfrey; Chaves, Sandra S.; Verani, Jennifer R.; Omer, Saad B.

doi:10.1016/j.vaccine.2022.05.014

Cited by 1 publication

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 In another study conducted in Kenya that examined messaging for maternal immunization, authors found that including relevant and relatable factors in messaging were most likely to result in positive attitudes toward maternal vaccination. 28 The results from our study add to this literature, specific to maternal GBS vaccine decision-making, and should be used to develop country-level readiness materials. Specifically related to vaccine hesitancy, ensuring that vaccine decision-makers and those that influence them have sufficient and relevant information about vaccine safety, are aware of their susceptibility to the disease, have an understanding related to the severity of the disease, and understand how the vaccine works and on what population will be critical for vaccine acceptance.…”

Section: Discussionmentioning

confidence: 65%

“Why has this new vaccine come and for what reasons?” key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya

Limaye,

Singh,

Fesshaye

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Group B streptococcus (GBS) is a leading global cause of neonatal sepsis and meningitis, stillbirth, and puerperal sepsis. While intrapartum antibiotic prophylaxis (IAP) is a currently available GBS disease prevention strategy, IAP is programmatically complex to implement, precluding use in low- and middle-income countries. In Kenya, 2% of stillbirths are attributable to GBS infection. Two maternal GBS vaccines are in late-stage clinical development. However, licensure of a maternal GBS vaccine does not translate into reduction of disease. We conducted 28 in-depth interviews with pregnant people, lactating people, and community members across two counties in Kenya to better understand the attitudes and informational needs of primary vaccine beneficiaries. We identified two emerging themes from the data. The first focused on antecedents to maternal GBS vaccine acceptability. The most common antecedents focused on the vaccine’s ability to protect the baby and/or the mother, followed by community sensitization before the vaccine was available. The second key theme focused on questions that would need to be addressed before someone could accept a maternal GBS vaccine. Three key categories of questions were identified, including vaccine safety compared to vaccine benefits, who gets the vaccine, and how the vaccine works. Realizing the potential benefits of a future GBS maternal vaccine will require a multifactorial approach, including ensuring that communities are aware of GBS-related harms as well as the safety and effectiveness of a maternal GBS vaccine. Our study contributes to informing this multifactorial approach by elucidating the attitudes and concerns of key populations.

show abstract

Section: Discussionmentioning

confidence: 65%